LakeShore Biopharma Stock (NASDAQ:LSB)


RevenueOwnershipFinancialsChart

Previous Close

$2.60

52W Range

$1.88 - $11.20

50D Avg

$4.45

200D Avg

$5.82

Market Cap

$47.51M

Avg Vol (3M)

$39.30K

Beta

0.74

Div Yield

-

LSB Company Profile


LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CN

Employees

758

IPO Date

Aug 05, 2021

Website

LSB Performance


LSB Financial Summary


Mar 23Mar 22Mar 21
Revenue$687.20M$502.95M$257.02M
Operating Income$-139.38M$-549.18K$-125.85M
Net Income$-145.48M$-545.73K$-191.83M
EBITDA$-76.82M$-549.18K$-116.78M
Basic EPS-$-0.02-
Diluted EPS-$-0.02-

Fiscal year ends in Mar 23 | Currency in USD